B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

Benzinga Newsdesk www.benzinga.com Negative 63.1%

Neg 63.1% Neu 0% Pos 0%

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.